Aveanna Healthcare Holdings Inc. (AVAH) fair value analysis
Nasdaq · Updated 2026-10-19
AVAH price how computed
Forward Fair Value verdict
Fairly valuedAVAH is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $12.34
- Sector
- Healthcare
- 12-month range
- $6.22–$14.38
- Market cap
- $2.69B
- From 52-week high
- -14.2%
- Shares outstanding
- 218M
- Rank in Healthcare by discount to fair value
- #61 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Aveanna Healthcare Holdings Inc. is a provider of home health and hospice services in the United States. The company operates across multiple states, delivering care services to patients in their homes.
AVAH currently ranks #61 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $2.69B
- P/E (trailing)
- 17x
- Revenue (TTM)
- $2.6B
- Net margin
- 10.6%
- EPS (TTM)
- $0.71
- Gross margin
- 32.6%
- Debt / equity
- 5.24
- Revenue growth (3-yr avg)
- 13.4%
- Shares outstanding
- 218M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 32 · neutral
- 50-day average
- $12.74
- 200-day average
- $9.01
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+31.2%)
2026-03 ▲ beat (+38.5%)
2025-12 ▲ beat (+28.9%)
2025-09 ▲ beat (+15.4%)
2025-06 ▲ beat (+1500.0%)
2025-03 ▲ beat (+2731.6%)
2024-12 ▲ beat (+10100.0%)
2024-09 ▲ beat (+300.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 3 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $14.8
- Target vs last price
- +19.9%
What our data shows for AVAH
- Our model validated 9 trailing price-to-earnings windows for AVAH, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $6.22–$14.38.
- The 14-day relative strength index sits at a neutral 32.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for AVAH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent AVAH news
TickrTrends' derived news-sentiment signal for AVAH is currently leaning positive, computed from recent coverage.
- Aveanna Announces Third Quarter 2026 Earnings Release Date and Conference Call (manilatimes.net, 2026-10-22)
TickrTrends take: Aveanna Healthcare's announcement of its third quarter 2026 earnings release date provides an upcoming opportunity for investors to assess whether the company's operational performance aligns with its current fairly valued status in the Healthcare sector. The earnings report will be a key data point for determining if recent business developments have shifted the company's fundamental valuation metrics relative to TickrTrends' current assessment. Investors tracking the company should monitor revenue trends, margin performance, and guidance updates during the earnings call to evaluate whether the fairly valued rating remains appropriate. - A Look at Aveanna Healthcare Holdings Inc (AVAH) After 3.2% Decline -- GF Value $5.66 vs Price $12.38 (gurufocus.com, 2026-09-25)
TickrTrends take: Aveanna Healthcare Holdings Inc operates in the Healthcare sector and is currently trading at a significant premium to its calculated intrinsic value, according to TickrTrends' valuation assessment. The stock's recent decline has not narrowed the gap between its market price and the estimated fair value, leaving it in overvalued territory based on fundamental analysis. Investors focused on valuation metrics should monitor whether the company's earnings growth or operational improvements can justify the current market premium, or whether further price adjustments may occur. - Aveanna Healthcare Holdings Inc (AVAH) Shares Fall 3.2% -- What GF Score of 63 Tells Investors (gurufocus.com, 2026-09-23)
TickrTrends take: Aveanna Healthcare's recent share decline occurs within a backdrop where TickrTrends currently assesses the company as overvalued. The GF Score of 63 suggests moderate fundamental quality, which may not adequately support the current valuation multiple in the Healthcare sector. Investors focused on valuation metrics should monitor whether further price adjustment occurs or if operational improvements strengthen the fundamental case for the company's current trading level.
More AVAH news
- Jim Cramer Compares Aveanna Healthcare (AVAH) With Hinge Health (HNGE) (finance.yahoo.com, 2026-09-18)
What people are saying
Follow the AVAH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — AVAH in the Healthcare sector is currently assessed as fairly valued. The 50/200-day trend state has shifted from an uptrend to a mixed state this week, indicating a change in the momentum indicators tracked by TickrTrends' derived metrics.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for AVAH show improvement this week as the company's sector discount rank moved from 93rd to 76th position among Healthcare sector peers. The valuation verdict shifted from Overvalued to Fairly valued, indicating that the stock's current price is now more aligned with its estimated intrinsic value relative to other companies in the Healthcare sector.
- 2026-09-21 — AVAH, a healthcare sector company, experienced several notable shifts in its derived indicators this week. The relative strength index moved from overbought territory into neutral range, while the stock's sector discount ranking declined from 77th to 93rd position. Most significantly, the valuation verdict changed from fairly valued to overvalued.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is AVAH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), AVAH is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is AVAH's TickrTrends verdict?
AVAH's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does AVAH compare to other Healthcare stocks?
AVAH ranks #61 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is AVAH overbought or oversold?
AVAH's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does AVAH report earnings next?
AVAH's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does AVAH usually beat earnings estimates?
Over its last 8 reported quarters AVAH beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AVAH?
Of 11 analysts covering AVAH, 8 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $14.8 (+19.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
AVAH vs A · AVAH vs ACHC · AVAH vs CLOV · AVAH vs COR · AVAH vs CVS